CTLA4 and glioblastoma: Furthermore, a combination of anti-CTLA-4 and anti-PD-1 antibodies have destroyed 75 percent of glioblastomas in mice, compared to 50 percent and 15 percent for anti-PD-1 and anti-CTLA-4 antibodies, as a monotherapy approach [225].